Replimune Group, Inc. — Director's Dealing 2023

Jul 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2023-07-10

Reporting Person: Esposito Pamela (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-10	Common Stock	M	15000	$3.30	Acquired	278436	Direct
2023-07-10	Common Stock	M	5000	$15.50	Acquired	283436	Direct
2023-07-10	Common Stock	S	17923	$21.63	Disposed	265513	Direct
2023-07-10	Common Stock	S	2077	$21.12	Disposed	263436	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-10	Employee Stock Option (right to buy)	$3.30	M	15000	Disposed	2027-07-26	Common Stock (15000)	Direct
2023-07-10	Employee Stock Option (right to buy)	$15.50	M	5000	Disposed	2029-04-01	Common Stock (5000)	Direct

Footnotes

F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.09 to $21.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 517,227 shares of the Issuer's common stock, 395,314 of which are exercisable as of the date hereof.

F5: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.

F6: The reporting person was granted an option to purchase 75,750 shares of the Issuer's common stock on April 1, 2019. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.